18 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
functions.
Factors that may inhibit our efforts to commercialize our diagnostic tests or therapeutic products on our own include:
our inability to recruit
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
to commercialize our diagnostic tests or therapeutic products on our own include:
our inability to recruit, train, and retain adequate numbers of effective sales
424B5
BIAF
BioAffinity Technologies Inc
8 Mar 24
Prospectus supplement for primary offering
12:18pm
on our own include:
our inability to recruit, train, and retain adequate numbers of effective sales, technical support, and marketing personnel
424B5
l4u 8gl3a
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
ps6h 8yve7fny2anv9u
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
26ym1iigapvz1sjng4w
16 Nov 23
Shelf registration
5:23pm
DRS
7pcf87gjfgpbh609cw
14 Aug 23
Draft registration statement
12:00am
8-K
EX-99.1
d835waaoumqgg p3
31 Mar 23
Results of Operations and Financial Condition
7:12pm
424B4
lwc5o qqw
2 Sep 22
Prospectus supplement with pricing info
3:25pm
S-1
02bme 4rpbsrtv96zjjz
25 Apr 22
IPO registration
6:16am
- Prev
- 1
- Next